Rapamycin: Something old, something new, sometimes borrowed and now renewed

Clinical Pharmacology and Therapeutics

Volumn 82, Issue 4, 2007, Pages 381-388

  Hartford, C M ^a   Ratain, M J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AP 23573; CARBAMAZEPINE; CYCLOSPORIN; CYTOCHROME P450 3A; DEXAMETHASONE; DRUG BINDING PROTEIN; ERYTHROMYCIN; EVEROLIMUS; FK 506 BINDING PROTEIN; GLYCOPROTEIN P; KETOCONAZOLE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHENOBARBITAL; PHENYTOIN; RAPAMYCIN; RIFAMPICIN; RITONAVIR; SIGNAL PEPTIDE; TEMSIROLIMUS;

ANEMIA; ANGIOGENESIS; ANOREXIA; AUTOPHAGY; CELL GROWTH; CELL PROLIFERATION; DIARRHEA; DRUG ABSORPTION; DRUG APPROVAL; DRUG COST; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FOOD DRUG INTERACTION; GRAFT REJECTION; GRAPEFRUIT JUICE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL PNEUMONIA; KIDNEY CARCINOMA; LEUKOPENIA; MUCOSA INFLAMMATION; NAUSEA; PNEUMONIA; PRIORITY JOURNAL; RASH; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANIMALS; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; DRUG INTERACTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MOLECULAR STRUCTURE; PROTEIN KINASES; SIGNAL TRANSDUCTION; SIROLIMUS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34548700597     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100317     Document Type: Review

References (104)

1. Wullschleger, S., Loewith, R. & Hall, M.N. TOR signaling in growth and metabolism. Cell 124, 471-484 (2006).
2. Sarbassov, D.D., Ali, S.M. & Sabatini, D.M. Growing roles for the mTOR pathway. Curr. Opin. Cell. Biol. 17, 596-603 (2005).
3. Avruch, J., Lin, Y., Long, X., Murthy, S. & Ortiz-Vega, S. Recent advances in the regulation of the TOR pathway by insulin and nutrients. Curr. Opin. Clin. Nutr. Metab. Care 8, 67-72 (2005).
4. Rowinsky, E.K. Targeting the molecular target of rapamycin (mTOR). Curr. Opin. Oncol. 16, 564-575 (2004).
5. Johannessen, C.M. et al. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc. Natl. Acad. Sci. USA 102, 8573-8578 (2005).
6. Faivre, S., Kroemer, G. & Raymond, E. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov. 5, 671-688 (2006).
7. Pende, M. et al. S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol. Cell. Biol. 24, 3112-3124 (2004).
8. Petroulakis, E., Mamane, Y., Le Bacquer, O., Shahbazian, D. & Sonenberg, N. mTOR signaling: implications for cancer and anticancer therapy. Br. J. Cancer 94, 195-199 (2006).
9. Kurmasheva, R.T., Huang, S. & Houghton, P.J. Predicted mechanisms of resistance to mTOR inhibitors. Br. J. Cancer 95, 955-960 (2006).
10. Huang, S., Bjornsti, M.A. & Houghton, P.J. Rapamycins: mechanism of action and cellular resistance. Cancer Biol. Ther. 2, 222-232 (2003).
11. Sehgal, S.N., Baker, H. & Vezina, C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J. Antibiot. (Tokyo) 28, 727-732 (1975).
12. Martel, R.R., Klicius, J. & Galet, S. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can. J. Physiol. Pharmacol. 55, 48-51 (1977).
13. Calne, R.Y. et al. Rapamycin for immunosuppression in organ allografting. Lancet 2, 227 (1989).
14. Kahan, B.D., Chang, J.Y. & Sehgal, S.N. Preclinical evaluation of a new potent immunosuppressive agent, rapamycin. Transplantation 52, 185-191 (1991).
15. Cardenas, M.E. et al. Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action. Clin. Microbiol. Rev. 12, 583-611 (1999).
16. Singh, N. & Heitman, J. Antifungal attributes of immunosuppressive agents: new paradigms in management and elucidating the pathophysiologic basis of opportunistic mycoses in organ transplant recipients. Transplantation 77, 795-800 (2004).
17. Dumont, F.J. & Su, Q. Mechanism of action of the immunosuppressant rapamycin. Life Sci. 58, 373-395 (1996).
18. Singh, K., Sun, S. & Vezina, C. Rapamycin (AY-22,989), a new antifungal antibiotic. IV. Mechanism of action. J. Antibiot. (Tokyo) 32, 630-645 (1979).
19. Kelly, P.A., Napoli, K. & Kahan, B.D. Conversion from liquid to solid rapamycin formulations in stable renal allograft transplant recipients. Biopharm. Drug Dispos. 20, 249-253 (1999).
20. Napoli, K.L. & Taylor, P.J. From beach to bedside: history of the development of sirolimus. Ther. Drug Monit. 23, 559-586 (2001).
21. Mahalati, K. & Kahan, B.D. Clinical pharmacokinetics of sirolimus. Clin. Pharmacokinet. 40, 573-585 (2001).
22. Kaplan, B., Meier-Kriesche, H.U., Napoli, K.L. & Kahan, B.D. The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent. Clin. Pharmacol. Ther. 63, 48-53 (1998).
23. Zimmerman, J.J., Ferron, G.M., Lim, H.K. & Parker, V. The effect of a high-fat meal on the oral bioavailability of the immunosuppressant sirolimus (rapamycin). J. Clin. Pharmacol. 39, 1155-1161 (1999).
24. Yatscoff, R., LeGatt, D., Keenan, R. & Chackowsky, P. Blood distribution of rapamycin. Transplantation 56, 1202-1206 (1993).
25. Zimmerman, J.J. et al. Pharmacokinetics of sirolimus (rapamycin) in subjects with mild to moderate hepatic impairment. J. Clin. Pharmacol. 45, 1368-1372 (2005).
26. Trepanier, D.J., Gallant, H., Legatt, D.F. & Yatscoff, R.W. Rapamycin: distribution, pharmacokinetics and therapeutic range investigations: an update. Clin. Biochem. 31, 345-351 (1998).
27. Kahan, B.D. et al. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. Clin. Transplant. 14, 97-109 (2000).
28. Stenton, S.B., Partovi, N. & Ensom, M.H. Sirolimus: the evidence for clinical pharmacokinetic monitoring. Clin. Pharmacokinet. 44, 769-786 (2005).
29. Chapman, T.M. & Perry, C.M. Everolimus. Drugs 64, 861-872 (2004); discussion 864-873.
30. Schuler, W. et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 64, 36-42 (1997).
31. Dudkin, L. et al. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin. Cancer Res. 7, 1758-1764 (2001).
32. Galanis, E. et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J. Clin. Oncol. 23, 5294-5304 (2005).
33. Yee, K.W. et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin. Cancer Res. 12, 5165-5173 (2006).
34. Mita, M.M. et al. Phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of AP23573, an mTOR inhibitor, administered IV daily X 5 every other week in patients (pts) with refractory or advanced malignancies. J. Clin. Oncol. (Meeting Abstracts) 22, 3076 (2004).
35. Kirchner, G.I., Meier-Wiedenbach, I. & Manns, M.P. Clinical pharmacokinetics of everolimus. Clin. Pharmacokinet. 43, 83-95 (2004).
36. Kovarik, J.M. et al. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin. Pharmacol. Ther. 69, 48-56 (2001).
37. Desai, A.A. et al. Development of a pharmacokinetic (PK) model and assessment of patient (pt) covariate effects on dose-dependent PK following different dosing schedules in two phase I trials of AP23573 (AP), a mTOR inhibitor. J. Clin. Oncol. (Meeting Abstracts) 23, 3043 (2005).
38. Cai, P., Tsao, R. & Ruppen, M.E. In Vitro Metabolic Study Of Temsirolimus: Preparation, Isolation, And Identification Of The Metabolites. Drug Metab Dispos 35, 1554-1563 (2007).
39. Jacobsen, W. et al. Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD. Transplant. Proc. 33, 514-515 (2001).
40. Kovarik, J.M. et al. Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. Clin. Pharmacol. Ther. 70, 425-430 (2001).
41. Neumayer, H.H. et al. Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients. Br. J. Clin. Pharmacol. 48, 694-703 (1999).
42. Hidalgo, M. et al. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin. Cancer Res. 12, 5755-5763 (2006).
43. Raymond, E. et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J. Clin. Oncol. 22, 2336-2347 (2004).
44. Zeng, Z. et al. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 109, 3509-3512 (2007).
45. Del Bufalo, D. et al. Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res. 66, 5549-5554 (2006).
46. Chawla, S.P. et al. Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas. J. Clin. Oncol. (Meeting Abstracts) 24, 9505 (2006).
47. Buhaescu, I., Izzedine, H. & Covic, A. Sirolimus - challenging current perspectives. Ther. Drug Monit. 28, 577-584 (2006).
48. Champion, L. et al. Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. Ann. Intern. Med. 144, 505-509 (2006).
49. Duran, I. et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur. J. Cancer 42, 1875-1880 (2006).
50. Rubinsztein, D.C., Gestwicki, J.E., Murphy, L.O. & Klionsky, D.J. Potential therapeutic applications of autophagy. Nat. Rev. Drug Discov. 6, 304-312 (2007).
51. Levy, G. et al. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl. 12, 1640-1648 (2006).
52. Snell, G.I. et al. Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial. Am. J. Transplant. 6, 169-177 (2006).
53. Keogh, A. et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 110, 2694-2700 (2004).
54. Kerkar, N. et al. Rapamycin successfully treats post-transplant autoimmune hepatitis. Am. J. Transplant. 5, 1085-1089 (2005).
55. Cutler, C. & Antin, J.H. Sirolimus for GVHD prophylaxis in allogeneic stem cell transplantation. Bone Marrow Transplant. 34, 471-476 (2004).
56. Benito, A.I. et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 72, 1924-1929 (2001).
57. Couriel, D.R. et al. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br. J. Haematol. 130, 409-417 (2005).
58. Fernandez, D., Bonilla, E., Mirza, N., Niland, B. & Perl, A. Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum. 54, 2983-2988 (2006).
59. Nadiminti, U. & Arbiser, J.L. Rapamycin (sirolimus) as a steroid-sparing agent in dermatomyositis. J. Am. Acad. Dermatol. 52, 17-19 (2005).
60. Valentini, R.P. et al. Sirolimus rescue for tacrolimus-associated post-transplant autoimmune hemolytic anemia. Pediatr. Transplant. 10, 358-361 (2006).
61. Foroncewicz, B., Mucha, K., Paczek, L., Chmura, A. & Rowinski, W. Efficacy of rapamycin in patient with juvenile rheumatoid arthritis. Transpl. Int. 18, 366-368 (2005).
62. Majewski, M. et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc. Natl. Acad. Sci. USA 97, 4285-4290 (2000).
63. Baeder, W.L., Sredy, J., Sehgal, S.N., Chang, J.Y. & Adams, L.M. Rapamycin prevents the onset of insulin-dependent diabetes mellitus (IDDM) in NOD mice. Clin. Exp. Immunol. 89, 174-178 (1992).
64. Ikeda, E., Hikita, N., Eto, K. & Mochizuki, M. Tacrolimus-rapamycin combination therapy for experimental autoimmune uveoretinitis. Jpn. J. Ophthalmol. 41, 396-402 (1997).
65. Martin, D.F., DeBarge, L.R., Nussenblatt, R.B., Chan, C.C. & Roberge, F.G. Synergistic effect of rapamycin and cyclosporin A in the treatment of experimental autoimmune uveoretinitis. J. Immunol. 154, 922-927 (1995).
66. Teachey, D.T. et al. Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS). Blood 108, 1965-1971 (2006).
67. Brown, V.I. et al. Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling. Proc. Natl. Acad. Sci. USA 100, 15113-15118 (2003).
68. Haczku, A. et al. The effect of dexamethasone, cyclosporine, and rapamycin on T-lymphocyte proliferation in vitro: comparison of cells from patients with glucocorticoid-sensitive and glucocorticoid-resistant chronic asthma. J. Allergy Clin. Immunol. 93, 510-519 (1994).
69. Valmori, D. et al. Rapamycin-mediated enrichment of T cells with regulatory activity in stimulated CD4+ T cell cultures is not due to the selective expansion of naturally occurring regulatory T cells but to the induction of regulatory functions in conventional CD4+ T cells. J. Immunol. 177, 944-949 (2006).
70. Uss, E., Yong, S.L., Hooibrink, B., van Lier, R.A. & ten Berge, I.J. Rapamycin enhances the number of alloantigen-induced human CD103+CD8+ regulatory T cells in vitro. Transplantation 83, 1098-1106 (2007).
71. Tian, L., Lu, L., Yuan, Z., Lamb, J.R. & Tam, P.K. Acceleration of apoptosis in CD4+CD8+ thymocytes by rapamycin accompanied by increased CD4+CD25+ T cells in the periphery. Transplantation 77, 183-189 (2004).
72. Chan, S. et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J. Clin. Oncol. 23, 5314-5322 (2005).
73. Atkins, M.B. et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. 22, 909-918 (2004).
74. Hudes, G. et al. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR+IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). J. Clin. Oncol. (Meeting Abstracts) 24, LBA4 (2006).
75. Hudes, G. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271-2281 (2007).
76. Hosoi, H. et al. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res. 59, 886-894 (1999).
77. Mateo-Lozano, S., Tirado, O.M. & Notario, V. Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation. Oncogene 22, 9282-9287 (2003).
78. Wan, X., Mendoza, A., Khanna, C. & Helman, L.J. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res. 65, 2406-2411 (2005).
79. Xu, Q., Thompson, J.E. & Carroll, M. mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood 106, 4261-4268 (2005).
80. Decker, T. et al. Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood 101, 278-285 (2003).
81. Haritunians, T. et al. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 21, 333-339 (2007).
82. Albert, J.M., Kim, K.W., Cao, C. & Lu, B. Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol. Cancer Ther. 5, 1183-1189 (2006).
83. Beuvink, I. et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120, 747-759 (2005).
84. Lee, L. et al. Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models. Genes Chromosomes Cancer 42, 213-227 (2005).
85. Laschke, M.W. et al. Rapamycin induces regression of endometriotic lesions by inhibiting neovascularization and cell proliferation. Br. J. Pharmacol. 149, 137-144 (2006).
86. Kwon, Y.S., Hong, H.S., Kim, J.C., Shin, J.S. & Son, Y. Inhibitory effect of rapamycin on corneal neovascularization in vitro and in vivo. Invest. Ophthalmol. Vis. Sci. 46, 454-460 (2005).
87. Recher, C. et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 105, 2527-2534 (2005).
88. Platzbecker, U. et al. Activity of sirolimus in patients with myelodysplastic syndrome - results of a pilot study. Br. J. Haematol. 128, 625-630 (2005).
89. Franz, D.N. et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann. Neurol. 59, 490-498 (2006).
90. Hausleiter, J. et al. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. Circulation 110, 790-795 (2004).
91. Moses, J.W. et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med. 349, 1315-1323 (2003).
92. Shillingford, J.M. et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc. Natl. Acad. Sci. USA 103, 5466-5471 (2006).
93. Shioi, T. et al. Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 107, 1664-1670 (2003).
94. Maeda, K. et al. Rapamycin ameliorates experimental autoimmune myocarditis. Int. Heart J. 46, 513-530 (2005).
95. Shegogue, D. & Trojanowska, M. Mammalian target of rapamycin positively regulates collagen type I production via a phosphatidylinositol 3-kinase-independent pathway. J. Biol. Chem. 279, 23166-23175 (2004).
96. Simler, N.R. et al. The rapamycin analogue SDZ RAD attenuates bleomycin-induced pulmonary fibrosis in rats. Eur. Respir. J. 19, 1124-1127 (2002).
97. Biecker, E. et al. Long-term treatment of bile duct-ligated rats with rapamycin (sirolimus) significantly attenuates liver fibrosis: analysis of the underlying mechanisms. J. Pharmacol. Exp. Ther. 313, 952-961 (2005).
98. Bonegio, R.G. et al. Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J. Am. Soc. Nephrol. 16, 2063-2072 (2005).
99. Ravikumar, B., Duden, R. & Rubinsztein, D.C. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum. Mol. Genet. 11, 1107-1117 (2002).
100. Ravikumar, B. et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet. 36, 585-595 (2004).
101. Heredia, A. et al. Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1. Proc. Natl. Acad. Sci. USA 100, 10411-10416 (2003).
102. Castedo, M. et al. Human immunodeficiency virus 1 envelope glycoprotein complex-induced apoptosis involves mammalian target of rapamycin/FKBP12-rapamycin-associated protein-mediated p53 phosphorylation. J. Exp. Med. 194, 1097-1110 (2001).
103. Harrington, L.S. et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell. Biol. 166, 213-223 (2004).
104. Um, S.H. et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431, 200-205 (2004).